New Developments in Pharmacological Treatment of Obesity and Type 2 DiabetesBeyond and within GLP 1 Receptor Agonists Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Obesity pharmacotherapy in older adults: a narrative review of evidence International Journal of Obesity